New in Cephalalgia!
•
Long-term treatment of atogepant for the preventive treatment of migraine was safe and well tolerated. Overall safety results across 156 weeks were consistent with the known safety profile of atogepant; no new safety signals were observed.
•
Efficacy and functional outcomes showed improvement from lead-in study baseline at weeks 13–16 and were consistent through 156 weeks.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience@MessoudAshina
New in Cephalalgia!
Across all countries, substantial humanistic and economic burden was reported in individuals with migraine and comorbid depression compared with individuals with migraine alone, emphasizing the need for comprehensive management and preventive strategies to cohesively address both conditions
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience
New in Cephalalgia!
A 10-year study developed and externally validated the Migraine Risk Stratification Score (MRSS) to stratify cryptogenic ischemic stroke (CIS) risk in patients with migraine and right-to-left shunt, with particular value for identifying individuals at low risk.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience
New in Cephalalgia Reports!
🧠 How much can we learn about a headache simply by asking the right questions?
When it comes to headache disorders, a good clinical history is often our most powerful diagnostic tool.
But effective history-taking is more than ticking boxes. It requires active listening, empathy, structured questioning, and clinical reasoning.
📢 A new article published in Cephalalgia Reports by the International Headache Society Education Committee presents a practical approach to optimising headache history-taking:
1️⃣ Listen and connect: Build rapport, ask open-ended questions, and understand the patient's experience.
2️⃣ Characterise the headache: Explore the onset, timing, pain characteristics, associated symptoms, triggers, and impact on daily life.
3️⃣ Check for red flags: Identify warning signs of secondary headaches using tools such as SNNOOP10 and careful assessment of temporal patterns.
4️⃣ Explain and plan: Communicate the diagnosis, address patient concerns, and develop a shared management plan.
💡 The key message?
Headache diagnosis is not just about recognising symptoms. It is about understanding the person experiencing them.
And while digital tools and AI may support clinical assessment, they cannot replace the art of listening.
📖 Read the full paper:
Souza MNP, et al. Optimizing headache history-taking: A structured approach from the International Headache Society Education Committee. Cephalalgia Reports. 2026;9.
🔗 doi.org/10.1177/251581632614…
💬 For clinicians: What is the one question you never forget to ask when taking a headache history?
#CephalalgiaReports#HeadacheMedicine#Migraine#Neurology#HeadacheEducation#InternationalHeadacheSociety#MedicalEducation
New in Cephalalgia!
The evidence cited in the letter supports giving UdH greater attention in future population studies and burden estimates. At the same time, its clinical course and the benefits of any specific intervention require further study.
The authors therefore regard UdH as an important research and public health consideration, without assuming that every child with brief or mild
headache requires treatment.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience@deryauluduz
New in Cephalalgia!
Some other headache was unaccounted for in these studies; moreover, it was common: the Turkish study, with 7,088 participants, estimated its 1-year prevalence as 29.2%.6 The study authors labelled it “undifferentiated headache” (UdH) (in terminological alignment with A3.6 Undifferentiated
trigeminal autonomic cephalalgia in ICHD-3).
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience
~4 million Australians live with migraine.
Yet our new paper found just ONE NHMRC/MRFF-funded headache clinical trial from 2013–2025, and NONE for migraine or tension-type headache.
We need stronger investment and research capacity.
New in Cephalalgia Reports!
Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change.
Article highlights
•
No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden.
•
A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache.
•
Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience@faradoost